Peptides News and Research

RSS

Research on immune system may help in healing chronic inflammatory diseases

Biochemists at Kiel University, along with international scientists, have identified an important messenger in the immune system. The messenger interleukin-27 plays an important role when the human body blocks inflammations.

9 Nov 2010

Raptor initiates dosing in DR Cysteamine Phase 2 clinical trial for Huntington's Disease

Raptor Pharmaceutical Corp., today announced that the first patient has been dosed in its Phase 2 clinical trial of DR Cysteamine for the potential treatment of Huntington's Disease. The Phase 2 clinical trial is being conducted under a previously announced collaboration agreement with The Centre Hospitalier Universitaire d'Angers ("CHU d'Angers"), which has commenced enrolling patients at eight clinical sites throughout France.

8 Nov 2010

Anti-TNF therapies may reduce Alzheimer's risk among people with rheumatoid arthritis

Anti-TNF therapies commonly used to treat rheumatoid arthritis have been found to potentially reduce the risk of developing Alzheimer's dementia among people with rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Early interference in entorhinal cortex may halt progression of Alzheimer's disease

New research is helping to unravel the events that underlie the "spread" of Alzheimer's disease (AD) throughout the brain. The research, published by Cell Press in the November 4th issue of the journal Neuron, follows disease progression from a vulnerable brain region that is affected early in the disease to interconnected brain regions that are affected in later stages. The findings may contribute to design of therapeutic interventions as targeting the brain region where AD originates would be simpler than targeting multiple brain areas.

4 Nov 2010

Scientists identify events that causes AD progression

Scientists at the Gladstone Institute of Neurological Disease (GIND) have offered new information about the events that underlie the "spread" of Alzheimer's disease (AD) throughout the brain.

4 Nov 2010

BioCurex files patent for synthetic peptide in RECAF test

BioCurex, Inc. today announced that it has filed a new patent within the Patent Cooperation Treaty, which presently includes 142 countries.

4 Nov 2010

Immunomedics product candidates, technologies receive recognition from QTDP program

Immunomedics, Inc. a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that all 12 applications from the Company were certified by the Internal Revenue Service of the Department of Treasury as qualified investments in accordance with the Qualifying Therapeutic Discovery Project (QTDP) program under section 48D of the Internal Revenue Code. As a result, the Company will receive an aggregate cash award of $2.9 million.

3 Nov 2010

Palatin receives $978,000 in grants under PPACA

Palatin Technologies, Inc., announced today that it has received $978,000 in grants under the Patient Protection and Affordable Care Act of 2010 (PPACA), with $847,000 available immediately and $131,000 available no later than 30 days after Palatin's fiscal year ending June 30, 2011.

2 Nov 2010

Isogenica enters collaborative agreement with University of Cambridge Professor

Isogenica Ltd today announced that it has entered into a collaborative agreement with Professor Sir Tom Blundell of the University of Cambridge.

2 Nov 2010

New findings pave way to improve early detection of ovarian cancer

A drug in testing to treat atherosclerosis significantly inhibited growth of ovarian cancer in both human cell lines and mouse models, the first such report of a peptide being used to fight malignancies, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center.

2 Nov 2010

Scientists identify potential new treatment for Nipah and Hendra viruses

Scientists at Weill Cornell Medical College have identified a potential new treatment for the Nipah and Hendra viruses, two lethal and emerging viruses for which there is currently no treatment or vaccine available. The approach could also lead to new therapies for measles, mumps and the flu. The new research appears in today's edition of the prestigious journal Public Library of Science (PLoS) Pathogens.

29 Oct 2010

Ipsen reports 8.3% increase in Group sales for first nine months of 2010

Ipsen reported today its sales for the third quarter and the first nine months of 2010.

28 Oct 2010

Compugen 2010 third quarter net loss decreases to $1.6 million from $1.9 million

Compugen Ltd. today reported financial results for the third quarter ending September 30, 2010.

26 Oct 2010

Lumiphore signs global cooperation with Algeta to integrate Lumi4 complexes

Lumiphore Inc., a portfolio company of Nanostart AG, has signed a global cooperation with Algeta ASA a leading company specializing in innovative radiopharmaceutical therapies to treat cancer patients. The agreement enables the integration of Lumiphore's Lumi4 complexes into the targeted radiotherapeutics and companion diagnostics from Algeta.

From Thermo Fisher Scientific Inc. 26 Oct 2010

New source of blood-derived biomarkers may help in cancer diagnosis

The future of cancer diagnosis may lie in just a few milliliters of blood, according to a research team led by Professor Arie Admon of the Technion-Israel Institute of Technology.

26 Oct 2010

DERMAGENICS Collagen Recovery Cream helps revitalize skin damaged by radiation, chemotherapy

Breast Cancer Awareness month spotlights the increasingly high incidence of breast cancer, and also brings attention to the question, "what is being done to speed and ease recovery?"

26 Oct 2010

Antigenics expands HSPPC-96 Phase 2 clinical study in glioma

Antigenics, Inc. today announced the expansion of a phase 2 clinical study of HSPPC-96 (Oncophage® vaccine; vitespen), Antigenics' personalized therapeutic cancer vaccine, in patients with newly diagnosed glioma.

25 Oct 2010

Revance presents results of RT001 two Phase 2b clinical trials for lateral canthal lines at Chicago annual meeting

Revance Therapeutics, Inc. today announced that the results of two Phase 2b clinical trials on RT001, a topical botulinum toxin type A which is under investigation for the treatment of lateral canthal lines (crow's feet wrinkles) were presented at the annual meeting of the American Society of Dermatologic Surgery in Chicago.

25 Oct 2010

Scientists find two proteins that regulates water retention in salt-sensitive hypertension

Research conducted by scientists at LSU Health Sciences Center New Orleans has found that two proteins in the brain act as valves to turn the hormone that regulates water retention in the body on and off. Their findings may lead to advances in treatment for diseases like high blood pressure, congestive heart failure, and cirrhosis of the liver. The research is published in the November 1, 2010 issue of Endocrinology.

25 Oct 2010

Biomarkers can improve ability to identify patients at high risk of CKD: Study

Measuring three biomarkers in a single blood sample may improve physicians' ability to identify patients at high risk of developing chronic kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.

22 Oct 2010

Peptides News and Research

Research on immune system may help in healing chronic inflammatory diseases

Raptor initiates dosing in DR Cysteamine Phase 2 clinical trial for Huntington's Disease

Anti-TNF therapies may reduce Alzheimer's risk among people with rheumatoid arthritis

Early interference in entorhinal cortex may halt progression of Alzheimer's disease

Scientists identify events that causes AD progression

BioCurex files patent for synthetic peptide in RECAF test

Immunomedics product candidates, technologies receive recognition from QTDP program

Palatin receives $978,000 in grants under PPACA

Isogenica enters collaborative agreement with University of Cambridge Professor

New findings pave way to improve early detection of ovarian cancer

Scientists identify potential new treatment for Nipah and Hendra viruses

Ipsen reports 8.3% increase in Group sales for first nine months of 2010

Compugen 2010 third quarter net loss decreases to $1.6 million from $1.9 million

Lumiphore signs global cooperation with Algeta to integrate Lumi4 complexes

New source of blood-derived biomarkers may help in cancer diagnosis

DERMAGENICS Collagen Recovery Cream helps revitalize skin damaged by radiation, chemotherapy

Antigenics expands HSPPC-96 Phase 2 clinical study in glioma

Revance presents results of RT001 two Phase 2b clinical trials for lateral canthal lines at Chicago annual meeting

Scientists find two proteins that regulates water retention in salt-sensitive hypertension

Biomarkers can improve ability to identify patients at high risk of CKD: Study

Editorial Focus eBook - Peptides and Oligonucleotides (2nd edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News